Results 111 to 120 of about 78,600 (311)

Maximum Likelihood Estimation of the Multivariate Normal Mixture Model [PDF]

open access: yes
The Hessian of the multivariate normal mixture model is derived, and estimators of the information matrix are obtained, thus enabling consistent estimation of all parameters and their precisions.
Boldea, Otilia, Magnus, Jan R.
core   +1 more source

The Mirage of Factor Equivalence: Examining the Complexities of Non‐Factor Therapies in Haemophilia

open access: yesHaemophilia, EarlyView.
ABSTRACT Background This article provides a critical analysis of the ‘factor equivalence’ concept as applied to non‐factor therapies (NFTs) for haemophilia, highlighting its limitations and clinical implications. Although factor equivalence estimates serve as a comparative tool for evaluating pro‐coagulant effects across different therapies, they may ...
Yesim Dargaud   +2 more
wiley   +1 more source

TREATMENT OF HEMOPHILIA WITH HUMAN FACTORIX PRODUCED IN MAMIMARY TISSUE OF TRANSGENIC MAMMALS [PDF]

open access: yes, 2008
Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention.
Drohan, William N.   +4 more
core   +1 more source

ORAL TREATMENT OF HEMOPHILIA [PDF]

open access: yes, 2007
Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome.
Alpan, Oral   +3 more
core   +1 more source

Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Haemophilia A and B are hereditary bleeding disorders that require multidisciplinary perioperative management. Data on orthopaedic surgery outcomes with extended‐half‐life (EHL) recombinant Fc‐fusion factor VIII (rFVIIIFc) and factor IX (rFIXFc) products remain limited.
Luigi Piero Solimeno   +10 more
wiley   +1 more source

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban

open access: yesHaematologica, 2018
Ida Martinelli   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy